In the BioHarmony Drug Report Database

"Preview" Icon

Aclidinium

Tudorza Pressair, Bretaris Genuair, Eklira Genuair (aclidinium) is a small molecule pharmaceutical. Aclidinium was first approved as Tudorza Pressair on 2012-07-20. It is used to treat bronchial spasm and chronic obstructive pulmonary disease in the USA. It has been approved in Europe to treat chronic obstructive pulmonary disease. The pharmaceutical is active against muscarinic acetylcholine receptor M3. In addition, it is known to target muscarinic acetylcholine receptor M4, muscarinic acetylcholine receptor M2, muscarinic acetylcholine receptor M5, and muscarinic acetylcholine receptor M1. Tudorza pressair’s patents are valid until 2029-03-13 (FDA).

 

Trade Name

 

Bretaris Genuair, Eklira Genuair
 

Common Name

 

aclidinium
 

ChEMBL ID

 

CHEMBL1194325
 

Indication

 

bronchial spasm, chronic obstructive pulmonary disease
 

Drug Class

 

Quaternary ammonium derivatives: muscarinic receptor antagonists

Image (chem structure or protein)

Aclidinium structure rendering